Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Raised approximately $83.6 million in gross proceeds from Initial Public OfferingAdvanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 ...
-
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
-
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
-
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
-
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
-
Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug resistant (MDR) Gram-negative infectionsInitiation of pivotal Phase 3 clinical trial in...
-
-Spero and Meiji Seika Pharma Co., LTD. announce an exclusive license partnership for SPR994 -FDA grants SPR994 Qualified Infectious Disease Product (QIDP) status for complicated urinary tract...
-
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
-
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
-
Cristina Larkin promoted to Chief Operating Officer Timothy Keutzer Promoted to Senior Vice President, Development CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a...